ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "immunology"

  • Abstract Number: 1231 • ACR Convergence 2022

    [68Ga]- CPCR4 Trifluoroacetate PET/CT Imaging of Chemokine Receptor CXCR4- Expression in Systemic Sclerosis Related Interstitial Lung Disease

    Chirag Rajkumar Kopp1, Shefali Sharma2, Venkata Subramanian Krishnaraju3, Chandra Bhushan Prasad3, Jagdeep Singh3, Shashi Anand3, Ranjana Minz3, Ashwani Sood3, Anindita Sinha3, Rajender Kumar Basher3, Sahajal Dhooria3, Varun Dhir4 and sanjay jain3, 1Post Graduate Institute of Medical Education and Research, Chandigarh, India, 2PGIMER< Chandigarh, Chandigarh, India, 3Postgraduate Institute of Medical Education and Research, Chandigarh, India, 4PGIMER, CHD, INDIA, Chandigarh, India

    Background/Purpose: Interstitial lung disease (ILD) in Systemic sclerosis (SSc) is a major contributor of morbidity and mortality. CXCR4/CXCL12 axis has been implicated in the pathogenesis…
  • Abstract Number: 1722 • ACR Convergence 2022

    The ERβ Agonist, WT-IV-012, Suppresses the Inflammatory Response in Systemic Lupus Erythematosus

    Shane Bruckner1, Braden Zeno1, William Willis2, Chad Bennett1 and Wael Jarjour1, 1The Ohio State University, Columbus, OH, 2Ohio State, Reynoldsburg, OH

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple organ damage, mainly affecting young women between the ages of 15 and 45…
  • Abstract Number: 2154 • ACR Convergence 2022

    An Exploratory Phosphoproteomic and Immunohistochemical Analysis of Receptor Tyrosine Kinases and Downstream Signaling Pathways in Systemic Sclerosis Skin

    Elizabeth Bundschuh1, Rebecca Fine2, Miruna Carnaru3, Sanchit Kumar4, Francis Perry Wilson2, Alyssa Williams1, Shannon Teaw4, Ian Odell4 and Monique Hinchcliff5, 1Yale University, New Haven, CT, 2Yale School of Medicine, New Haven, CT, 3Hartford Healthcare Medical Group, Rocky Hill, CT, 4Yale University School of Medicine, New Haven, CT, 5Yale School of Medicine, Westport, CT

    Background/Purpose: Receptor tyrosine kinases (RTK) such as epidermal growth factor receptor (EGFR) and others including PDGFRs, FGFRs, and VEGFRs are implicated in systemic sclerosis (SSc)…
  • Abstract Number: 0144 • ACR Convergence 2022

    The Association of Hypocomplementemia with Organ Involvement and Serum IgG4 in IgG4-related Disease

    Guy Katz1, Amelia S. Cogan1, Grace McMahon1, Sebastian Perez-Espina1, Ana Fernandes1, Cory Perugino1, Zachary Wallace1, John Atkinson2, Alfred Kim2 and John Stone3, 1Massachusetts General Hospital, Boston, MA, 2Washington University School of Medicine, St. Louis, MO, 3Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

    Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic immune-mediated disease that can affect nearly every organ in the body. Hypocomplementemia is common in some patients with…
  • Abstract Number: 0629 • ACR Convergence 2022

    The Cellular Metabolism of SLE NK Cells Is Primarily Altered at the Level of Mitochondrial Respiration

    Natalia Fluder, Morgane Humbel, camillo Ribi and Denis Comte, Service of Immunology and Allergy / CHUV, Lausanne, Switzerland

    Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic inflammatory disorder, which involves a loss of tolerance and development of autoantibodies. The role of Natural Killer…
  • Abstract Number: 0785 • ACR Convergence 2022

    Humoral Immune Responses Following Four SARS-CoV-2 Vaccine Doses or COVID-19 Infection in Patients with Immune-Mediated Inflammatory Diseases on Immunosuppressive Therapy: A Prospective Cohort Study

    Hilde Ørbo1, Kristin Hammersbøen Bjørlykke2, Joe Sexton1, Anne Therese Tveter1, Ingrid Jyssum1, Ingrid Egeland Christensen1, David Warren3, Tore K. Kvien1, Adity Chopra4, Grete Birkeland Kro3, Jørgen Jahnsen2, Ludvig A. Munthe3, Espen Haavardsholm1, Gunnveig Grødeland3, Sella Aarrestad Provan1, Kristin Kaasen Jørgensen2, Silje Watterdal Syversen1 and Guro Løvik Goll1, 1Diakonhjemmet Hospital, Oslo, Norway, 2Akershus University Hospital, Oslo, Norway, 3Oslo University Hospital, Oslo, Norway, 4Oslo University Hospital, Oslo, Oslo, Norway

    Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapy have impaired humoral immune responses to SARS-CoV-2 vaccination. This study aimed to assess serologic response…
  • Abstract Number: 1327 • ACR Convergence 2022

    Immune Cell Subsets and Risk of Incident Hip Fracture in Older Adults: The Cardiovascular Health Study

    Rachel Elam1, Petra Buzkova2, Joseph Delaney3, Howard Fink4, Joshua Barzilay5, Laura Carbone1, Rick Saha1, John Robbins6, Kenneth Mukamal7, Rodrigo Valderrabano8, Bruce Psaty2, Russell Tracy9, Nels Olson9, Sally Huber10, Margaret Doyle9, Alan Landay11 and Jane Cauley12, 1Augusta University, Augusta, GA, 2University of Washington, Seattle, WA, 3University of Manitoba, Winnipeg, MB, Canada, 4University of Minnesota, Minneapolis, MN, 5Kaiser Permanente, Atlanta, GA, 6UC Davis, Davis, CA, 7Beth Israel Deaconess Medical Center, Boston, MA, 8Brigham and Women's Hospital, Boston, MA, 9University of Vermont, Burlington, VT, 10University of Vermont, Burlingon, VT, 11Rush University Medical Center, Chicago, IL, 12University of Pittsburgh, PIttsburgh, PA

    Background/Purpose: Cell-mediated immunity may play a role in osteoporosis development. Fracture is the major consequence of osteoporosis. Thus, cell-mediated immunity may impact fracture risk. We…
  • Abstract Number: 1726 • ACR Convergence 2022

    Impaired Dynamic X-Chromosome Inactivation Maintenance in T Lymphocytes Is a Feature of Spontaneous Lupus in Female Mice and Is Exacerbated in Female-Biased Disease Models

    Nikhil Jiwrajka1, Natalie Toothacre2, Zachary Beethem2, Sarah Sting2, Katherine Forsyth2, Amanda Driscoll2, William Stohl3 and Montserrat Anguera2, 1Division of Rheumatology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 2Department of Biomedical Sciences, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, 3University of Southern California, Los Angeles, CA

    Background/Purpose: SLE is highly female-biased, yet the molecular origins of this bias remain unclear. The X chromosome contains many immune-related genes, suggesting that X-linked epigenetic…
  • Abstract Number: 2181 • ACR Convergence 2022

    Gut Microbe-derived Short-Chain Fatty Acids Regulate Arthritis and Myositis During Chikungunya Virus Infection

    Fang R. Zhao1, Emma Winkler1, Chun-Jun Guo2, Russell B. Williams3, Leran Wang1, Ana Jung1, Lindsay Droit1, Leah Heath1, Ting-ting Li2, Matthias Mack4, Megan T. Baldridge1, Thaddeus S. Stappenbeck5, Larissa B. Thackray1, Scott A. Handley1, Michael A. Fischbach6 and Michael S. Diamond1, 1Washington University in St. Louis, St. Louis, MO, 2Cornell University, New York, NY, 3Donald Danforth Plant Science Center, St. Louis, MO, 4University Hospital Regensburg, Regensburg, Germany, 5Cleveland Clinic, Cleveland, OH, 6Stanford University, Stanford, CA

    Background/Purpose: The intestinal microbiota regulates musculoskeletal inflammation and antibiotic use increases risk for the development or relapse of inflammatory arthritis. However, the basis for this…
  • Abstract Number: L02 • ACR Convergence 2021

    COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases

    Ines Colmegna1, Mariana Useche1, Emmanouil Rampakakis2, Nathalie Amiable3, Emmanuelle Rollet-Labelle3, Louis Bessette4, Jo-Anne Costa4, Marc Dionne4, Mary-Ann Fitzcharles2, Elizabeth Hazel2, Deirdre McCormack2, Laetitia Michou4, Pantelis Panopalis2, Marc-Andre Langlois5, Sasha Bernatsky6 and Paul R. Fortin7, 1The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 2McGill University Health Centre, Montreal, QC, Canada, 3Centre de Recherche du CHU de Quebec, Quebec, Canada, 4Universite Laval, Quebec, QC, Canada, 5University of Ottawa, Ottawa, ON, Canada, 6McGill University, Montreal, QC, Canada, 7CHU de Quebec - Universite Laval, Quebec, Canada

    Background/Purpose: Immunocompromised conditions and/or a history of autoimmune disease were exclusion criteria of the initial SARS-CoV-2 vaccines clinical trials. We assessed the safety and immunogenicity…
  • Abstract Number: L20 • ACR Convergence 2021

    Efficacy of Emapalumab, an Anti-IFNγ Antibody in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (sJIA) Who Had Failed High-Dose Glucocorticoids (GCs)

    Fabrizio De Benedetti1, Alexei Grom2, Paul Brogan3, Claudia Bracaglia1, Manuela Pardeo1, Giulia Marucci1, Despina Eleftheriou3, Charalampia Papadopoulou3, Pierre Quartier4, Jordi Antón5, Rikke Frederiksen6, Veronica Asnaghi6 and Cristina De Min6, 1Bambino Gesù Children's Hospital IRCCS, Rome, Italy, 2Cincinnati Children’s Hospital, Division of Rheumatology, Cincinnati, OH, 3UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, 4Université de Paris, IMAGINE Institute, RAISE reference centre, Pediatric Immuno-Hematology and Rheumatology Unit, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, 5Hospital Sant Joan de Déu, Division of Pediatric Rheumatology, University of Barcelona, Barcelona, Spain, 6Swedish Orphan Biovitrum AG (Sobi), Basel, Switzerland

    Background/Purpose: MAS is a life-threatening complication of rheumatic diseases, occurring most frequently in sJIA. The mainstay of MAS treatment is high dose GCs; however, GCs…
  • Abstract Number: 0024 • ACR Convergence 2021

    Heterogeneity of Inflammatory HLA-DR+ Synovial Fibroblasts in Rheumatoid Arthritis Is Driven by Responses to Leukocyte-Derived Cytokines

    Melanie Smith1, Alejandro Kochen1, Vianne Gao2, Michail Schizas2, Edward DiCarlo1, Susan Goodman1, Christina Leslie3, Laura Donlin1 and Alexander Rudensky4, 1Hospital for Special Surgery, New York, NY, 2Memorial Sloan Kettering Cancer Center, New York, NY, 3Computational and Systems Biology Program Memorial Sloan Kettering Cancer Center, New York, NY, 4Memorial Sloan Kettering Cancer Center / Howard Hughes Medical Institute, New York, NY

    Background/Purpose: Treatment-refractory rheumatoid arthritis (RA) represents a major unmet need with substantial societal burden. Targeting RA-associated fibroblast-like synoviocytes (FLS) may provide a less-immunosuppressive therapeutic option.…
  • Abstract Number: 0698 • ACR Convergence 2021

    Flow Cytometry and Sorting of Single Antibody Secreting Cells from Frozen Muscle Tissue

    Andrew Zlobin, Peter Pytel and Vladimir Liarski, University of Chicago, Chicago, IL

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) – dermatomyositis (DM), polymyositis, and inclusion body myositis - are poorly understood autoimmune muscle disorders. Isolation of relevant immune cell…
  • Abstract Number: 1512 • ACR Convergence 2021

    Epigenetic and Transcriptional Programs of CD4+ T Cell Anergy

    Philip Titcombe, Milagros Silva Morales and Daniel Mueller, University of Minnesota, Minneapolis, MN

    Background/Purpose: T cell tolerance is essential for preventing autoimmune diseases and resolving inflammation. To maintain tolerance, CD4+ T cells recognizing self-antigens in the periphery can…
  • Abstract Number: 0025 • ACR Convergence 2021

    The Modulatory Capacity of Galectin-3 on the Programmed Death-1 Signaling Axis in Rheumatoid Arthritis

    Kathrine Pedersen1, Morten Aagaard Nielsen2, Malene Hvid1, Bent Deleuran1 and Stinne Greisen1, 1Aarhus University, Aarhus, Denmark, 2Aarhus University / Aarhus University Hopital, Aarhus, Denmark

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation of the synovium. Despite a variety of treatments, 30-40% of RA patients fail…
  • « Previous Page
  • 1
  • …
  • 24
  • 25
  • 26
  • 27
  • 28
  • …
  • 33
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology